This week, BAT scientists are attending the Genetic Toxicology Association’s (GTA) annual meeting in Delaware.
We’re presenting some of our latest in vitro data on next-generation products and taking part in workshops discussing latest developments in biological assessment. Find us from 2nd May to see what we’re up to.
Wednesday 2nd May | Industry Workshop (1-6pm):
Latest Developments in Regulation and Assessment of Combustible and Alternative Tobacco Products
BAT Presenter: Marianna Gaca
Thursday 3rd May | Poster Sessions (5-7pm):
The pre-clinical assessment of a tobacco heating product (gloTM)
Authors: Marianna Gaca, David Thorne, Damien Breheny, Chuan Liu, James Murphy, and Chris Proctor.
The in vitro biological assessment of a novel hybrid tobacco product and comparison with cigarette smoke
Authors: Damien Breheny, Jason Adamson, Andrew Baxter, Ian Crooks, Tomasz Jaunky, Mark Taylor, David Thorne, Chuan Liu, James Murphy, and Marianna Gaca.
The effect of flavourings on the in vitro mutagenic and genotoxic potential of total particulate matter and gas vapour phase generated from a tobacco heating product
Authors: Ian Crooks, Theo Le Godec, Lorna Reynolds, Louise Neilson, Ken Scott, and Clive Meredith.
The chemical and mutagenic assessment of an electronic cigarette
Authors: David Thorne, Damien Breheny, Ian Crooks, Frazer Lowe, Jason Adamson, Kevin McAdam, Christopher Proctor, and Marianna Gaca.
A novel approach for the screening of e-cigarette aerosols using an Ames whole aerosol assay
Authors: David Thorne, Michael Hollings, Adam Seymour, Ian Crooks, Clive Meredith, and Marianna Gaca.
All poster materials will be fully available online after the event, however, be sure to come by
and meet us if you’re at the conference!
If however, you cannot attend, then keep an eye on our Twtter (@BAT_Sci) feed throughout the week for updates on all our activities.
*Please note all times are local – EST
Notes to Editors
About British American Tobacco: British American Tobacco is a global tobacco and Next Generation Product company with brands sold in more than 200 markets. It employs more than 50,000 people worldwide and has over 200 brands in its portfolio, with its cigarettes chosen by one in eight of the world’s one billion smokers. Leading global brands include Dunhill, Kent, Pall Mall and Lucky Strike.
About Next Generation Products (NGP): Next Generation Products is part of the British American Tobacco Group and is focused on developing and delivering high-quality alternative nicotine and tobacco products for adult consumers in the key areas of Vapour, Oral and Tobacco Heating Products. For more information see www.goVype.com and www.bat-science.com.
About Tobacco Harm Reduction: The only way to avoid the risks associated with tobacco use is not to consume tobacco at all, and the best way to reduce the risks is to stop using tobacco. However, the concept of harm reduction is increasingly being considered in relation to tobacco use. Harm reduction is about finding practical ways to minimise the health impact of an inherently risky activity or behaviour, without seeking to stop it entirely. It is a key element of BAT’s business strategy and is being discussed by some regulators. We think it’s important to work towards producing consumer-acceptable, potentially reduced risk products. We believe that tobacco regulatory policies should include harm reduction approaches for the millions of adults globally who will continue to consume tobacco products.
The Public Health Impact of e-cigarettes: Many in the public health community believe e-cigarettes offer great potential for contributing to tobacco harm reduction policies. A 2018 updated evidence review by Public Health England*, an executive body of the UK Department of Health, concludes that vaping is around 95% less harmful than smoking cigarettes. The UK’s Royal College of Physicians have said that the public can be reassured that e-cigarettes are much safer than smoking and that they should be widely promoted as a substitute for smoking.
For more information: email Joanna_Hunt@bat.com or call +44 (0)7858 375461